DE69733263D1 - Markierte elastase-inhibitoren - Google Patents

Markierte elastase-inhibitoren

Info

Publication number
DE69733263D1
DE69733263D1 DE69733263T DE69733263T DE69733263D1 DE 69733263 D1 DE69733263 D1 DE 69733263D1 DE 69733263 T DE69733263 T DE 69733263T DE 69733263 T DE69733263 T DE 69733263T DE 69733263 D1 DE69733263 D1 DE 69733263D1
Authority
DE
Germany
Prior art keywords
marked
elastase inhibitors
elastase
inhibitors
marked elastase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69733263T
Other languages
English (en)
Other versions
DE69733263T2 (de
Inventor
Karen Jane Barnes
Gary Robert Bower
Alan Michael Forster
Peter Knox
Marivi Mendizabal
Anthony Eamon Storey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
Amersham PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham PLC filed Critical Amersham PLC
Application granted granted Critical
Publication of DE69733263D1 publication Critical patent/DE69733263D1/de
Publication of DE69733263T2 publication Critical patent/DE69733263T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0444—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69733263T 1996-09-16 1997-09-10 Markierte elastase-inhibitoren Expired - Fee Related DE69733263T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96306718 1996-09-16
EP96306718 1996-09-16
PCT/GB1997/002467 WO1998010800A2 (en) 1996-09-16 1997-09-10 Labelled elastase inhibitors

Publications (2)

Publication Number Publication Date
DE69733263D1 true DE69733263D1 (de) 2005-06-16
DE69733263T2 DE69733263T2 (de) 2006-01-12

Family

ID=8225085

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733263T Expired - Fee Related DE69733263T2 (de) 1996-09-16 1997-09-10 Markierte elastase-inhibitoren

Country Status (8)

Country Link
US (1) US6375926B1 (de)
EP (1) EP0927049B1 (de)
JP (1) JP2001500152A (de)
AU (1) AU4214897A (de)
CA (1) CA2265945A1 (de)
DE (1) DE69733263T2 (de)
ES (1) ES2242230T3 (de)
WO (1) WO1998010800A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005204A1 (fr) * 1998-07-23 2000-02-03 Shionogi & Co., Ltd. COMPOSES DE β-LACTAME MONOCYCLIQUES ET INHIBITEURS DE LA CHYMASE LES RENFERMANT
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7678767B2 (en) * 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US20050281796A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
WO2006014567A2 (en) * 2004-07-08 2006-02-09 Pneumrx, Inc. Pleural effusion treatment device, method and material
US8722937B2 (en) 2006-02-27 2014-05-13 University Of South Florida Asymmetric disulfides and aryl-alkyl disulfides as anti-bacterial agents
US7846920B2 (en) * 2006-09-13 2010-12-07 University Of South Florida Heterosubstituted N-thiolated beta-lactam compounds and methods of use
WO2008036763A2 (en) * 2006-09-20 2008-03-27 Pneumrx, Inc. Tissue adhesive compositions and methods thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091514A (en) * 1987-03-26 1992-02-25 Neorx Corporation Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy
US5486529A (en) 1992-04-16 1996-01-23 Zeneca Limited Certain pyridyl ketones for treating diseases involving leukocyte elastase
GB9211783D0 (en) * 1992-06-04 1992-07-15 Ici Plc Amide derivatives
US5986076A (en) * 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
GB9502152D0 (en) 1995-02-03 1995-03-29 Zeneca Ltd Proline derivatives

Also Published As

Publication number Publication date
EP0927049B1 (de) 2005-05-11
ES2242230T3 (es) 2005-11-01
AU4214897A (en) 1998-04-02
CA2265945A1 (en) 1998-03-19
EP0927049A2 (de) 1999-07-07
WO1998010800A2 (en) 1998-03-19
JP2001500152A (ja) 2001-01-09
WO1998010800A3 (en) 1998-05-07
US6375926B1 (en) 2002-04-23
DE69733263T2 (de) 2006-01-12

Similar Documents

Publication Publication Date Title
FI963597A0 (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
DE69724809D1 (de) Refluxinhibitoren
FI972160A (fi) Matriisimetalloproteaasi-inhibiittorit
ID18142A (id) Inhibitor metaloprotease 1,4-heterosiklik
PT936912E (pt) Inibidores de cisteina protease
ID18141A (id) Inhibitor metaloprotease 1,3-diheterosiklik
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
ID18417A (id) Inhibitor ditentat metaloprotease
BR9707086A (pt) Inibidores de proteinase aspartila
DE69736109D1 (de) Differenzierungsinhibitor
DE69733263D1 (de) Markierte elastase-inhibitoren
DE69720957T2 (de) Ace-hemmer
KR970058619U (ko) 공동용 납골함
DK82096A (da) Varmevekslingsindretning
DE59707895D1 (de) Polyformamide
NO992480L (no) Line
FI963434A0 (fi) Kraftoeverfoeringsanordning till rotationskolvmotor
FI963590A0 (fi) Flaens till kabeltrumma
FI961302A0 (fi) Stoerstraolningsskydd till kabelgemomfoeringar
FI961517A0 (fi) Tillaeggsanordning till snoeskoter
FI962452A0 (fi) Krok till fiskredskap
FI960535A0 (fi) Kraftoeverfoeringsanordning till dubbelkretsloppmotor
FI962475A0 (fi) Draggenerator till kombinationspanna

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: GE HEALTHCARE LTD., LITTLE CHALFONT, BUCKINGHAMSHI

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee